当前位置: 首页 >> 检索结果
301. Alteplase for Posterior Circulation Ischemic Stroke at 4.5 to 24 Hours.
作者: Shenqiang Yan.;Ying Zhou.;Maarten G Lansberg.;David S Liebeskind.;Changzheng Yuan.;Han Yu.;Fujian Chen.;Hongfang Chen.;Bing Zhang.;Lingqun Mao.;Xiaoling Zhang.;Xiaona Wang.;Xuting Zhang.;Yi Chen.;Huan Zhou.;Wansi Zhong.;Yaode He.;Kun Chen.;Jianbing Wang.;Hui Chen.;Yuhui Huang.;Bruce C V Campbell.;Min Lou.; .
来源: N Engl J Med. 2025年392卷13期1288-1296页
The effects and risks of the use of intravenous thrombolysis between 4.5 and 24 hours after the onset of a posterior circulation ischemic stroke are not well studied.
302. Sotatercept in Patients with Pulmonary Arterial Hypertension at High Risk for Death.
作者: Marc Humbert.;Vallerie V McLaughlin.;David B Badesch.;H Ardeschir Ghofrani.;J Simon R Gibbs.;Mardi Gomberg-Maitland.;Ioana R Preston.;Rogerio Souza.;Aaron B Waxman.;Victor M Moles.;Laurent Savale.;Carmine Dario Vizza.;Stephan Rosenkranz.;Yaru Shi.;Barry Miller.;Harald S Mackenzie.;Samuel S Kim.;Maria José Loureiro.;Mahesh J Patel.;Joerg Koglin.;Alexandra G Cornell.;Marius M Hoeper.; .
来源: N Engl J Med. 2025年392卷20期1987-2000页
Sotatercept improves exercise capacity and delays the time to clinical worsening in patients with World Health Organization (WHO) functional class II or III pulmonary arterial hypertension. The effects of add-on sotatercept in patients with advanced pulmonary arterial hypertension and a high risk of death are unclear.
303. Pulsed Field or Cryoballoon Ablation for Paroxysmal Atrial Fibrillation.
作者: Tobias Reichlin.;Thomas Kueffer.;Patrick Badertscher.;Peter Jüni.;Sven Knecht.;Gregor Thalmann.;Nikola Kozhuharov.;Philipp Krisai.;Corinne Jufer.;Jens Maurhofer.;Dik Heg.;Tiago V Pereira.;Felix Mahfoud.;Helge Servatius.;Hildegard Tanner.;Michael Kühne.;Laurent Roten.;Christian Sticherling.; .
来源: N Engl J Med. 2025年392卷15期1497-1507页
Pulmonary-vein isolation is an effective treatment for paroxysmal atrial fibrillation. Pulsed field ablation (PFA) is a nonthermal ablation method with few adverse effects beyond the myocardium. Data are lacking on outcomes after PFA as compared with cryoballoon ablation as assessed with continuous rhythm monitoring.
304. Routine Cerebral Embolic Protection during Transcatheter Aortic-Valve Implantation.
作者: Rajesh K Kharbanda.;James Kennedy.;Zahra Jamal.;Matthew Dodd.;Richard Evans.;Kiran K Bal.;Alexander D Perkins.;Daniel J Blackman.;David Hildick-Smith.;Adrian P Banning.;Andreas Baumbach.;Peter Ludman.;Stephen Palmer.;Rodney H Stables.;Robert Henderson.;Clare Appleby.;James Cotton.;Nick Curzen.;Muhiddin Ozkor.;Jonathan Byrne.;Rajesh Aggarwal.;Rajiv Das.;Sagar Doshi.;Stuart Watkins.;Douglas F Muir.;Richard Anderson.;Saqib Chowdhary.;Richard Varcoe.;Stephen Dorman.;Sam Firoozi.;Raj Chelliah.;Colum Owens.;Simon Redwood.;Bernard Prendergast.;Javaid Iqbal.;Karim Ratib.;Ciprian Dospinescu.;Venkatesan Suresh.;Nicholas Cruden.;Thirumaran Rajathurai.;Iqbal S Malik.;Andrew Wiper.;Charis Costopoulos.;Ayush Khurana.;Amerjeet Banning.;Tim Clayton.; .
来源: N Engl J Med. 2025年
Transcatheter aortic-valve implantation (TAVI) is associated with procedure-related stroke. Cerebral embolic protection (CEP) devices may reduce embolization to the cerebral circulation and hence the incidence of stroke.
306. Global Effect of Cardiovascular Risk Factors on Lifetime Estimates.
作者: .;Christina Magnussen.;Jesus Alegre-Diaz.;Lubna A Al-Nasser.;Philippe Amouyel.;Larissa Aviles-Santa.;Stephan J L Bakker.;Christie M Ballantyne.;Antonio Bernabé-Ortiz.;Martin Bobak.;Paolo Boffetta.;Hermann Brenner.;Mattias Brunström.;Gunay Can.;Rodrigo M Carrillo-Larco.;William Checkley.;Jean Dallongeville.;Dirk De Bacquer.;Giovanni de Gaetano.;James A de Lemos.;Eleonora di Carluccio.;Annette Dobson.;Chiara Donfrancesco.;Marcus Dörr.;Eleonora d'Orsi.;Wojciech Drygas.;Robin P F Dullaart.;Gunnar Engström.;Marco M Ferrario.;Jean Ferrières.;Gemma A Figtree.;Bamba Gaye.;Majid Ghayour-Mobarhan.;Uri Goldbourt.;Clicerio Gonzalez.;Alina Gossling.;Guido Grassi.;Prakash C Gupta.;Jiang He.;Allison M Hodge.;Atsushi Hozawa.;Kristian Hveem.;Licia Iacoviello.;M Kamran Ikram.;Manami Inoue.;Vilma Irazola.;Modou Jobe.;Pekka Jousilahti.;Pontiano Kaleebu.;Maryam Kavousi.;Frank Kee.;Davood Khalili.;Jens Klotsche.;Wolfgang Koenig.;Anna Kontsevaya.;Sudhirsen Kowlessur.;Pablo Kuri-Morales.;Kari Kuulasmaa.;Sun-Seog Kweon.;Karl J Lackner.;Ulf Landmesser.;David M Leistner.;Carlos E Leiva Sisnieguez.;Darryl Leong.;Lars Lind.;Allan Linneberg.;Thiess Lorenz.;Magnus N Lyngbakken.;Reza Malekzadeh.;Sofia Malyutina.;Ellisiv B Mathiesen.;Patrick McElduff.;Olle Melander.;Andres Metspalu.;J Jaime Miranda.;Marie Moitry.;Joseph Mugisha.;Julia Munzinger.;Mahdi Nalini.;Vijay Nambi.;Peter M Nilsson.;Toshiharu Ninomiya.;Torbjørn Omland.;Sok King Ong.;Karen Oppermann.;Andrzej Pajak.;Luigi Palmieri.;Demosthenes Panagiotakos.;Sue K Park.;Mangesh S Pednekar.;Arokiasamy Perianayagam.;Annette Peters.;Hossein Poustchi.;Dorairaj Prabhakaran.;Andrew M Prentice.;Eva Prescott.;Arshed Quyyumi.;Ulf Risérus.;Satoko Sakata.;Martin Salazar.;Veikko Salomaa.;Susana Sans.;E Lilian P Sattler.;Ben Schöttker.;Aletta E Schutte.;Sadaf G Sepanlou.;Sanjib K Sharma.;Jonathan Shaw.;Leon A Simons.;Stefan Söderberg.;Abdonas Tamosiunas.;Roberto Tapia-Conyer.;Barbara Thorand.;Hugh Tunstall-Pedoe.;Jaakko Tuomilehto.;Raphael Twerenbold.;Diego Vanuzzo.;Giovanni Veronesi.;S Goya Wannamethee.;Masafumi Watanabe.;Jessica Weimann.;Philipp S Wild.;Yao Yao.;Yi Zeng.;Andreas Ziegler.;Francisco M Ojeda.;Stefan Blankenberg.
来源: N Engl J Med. 2025年
Five risk factors account for approximately 50% of the global burden of cardiovascular disease. How the presence or absence of classic risk factors affects lifetime estimates of cardiovascular disease and death from any cause remains unclear.
309. Lepodisiran - A Long-Duration Small Interfering RNA Targeting Lipoprotein(a).
作者: Steven E Nissen.;Wei Ni.;Xi Shen.;Qiuqing Wang.;Ann Marie Navar.;Stephen J Nicholls.;Kathy Wolski.;Laura Michael.;Axel Haupt.;John H Krege.; .
来源: N Engl J Med. 2025年392卷17期1673-1683页
Elevated lipoprotein(a) concentrations are associated with atherosclerotic cardiovascular disease. The safety and efficacy of lepodisiran, an extended-duration, small interfering RNA targeting hepatic synthesis of lipoprotein(a), are unknown.
310. Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes.
作者: Darren K McGuire.;Nikolaus Marx.;Sharon L Mulvagh.;John E Deanfield.;Silvio E Inzucchi.;Rodica Pop-Busui.;Johannes F E Mann.;Scott S Emerson.;Neil R Poulter.;Mads D M Engelmann.;Maria Sejersten Ripa.;G Kees Hovingh.;Kirstine Brown-Frandsen.;Stephen C Bain.;Matthew A Cavender.;Mette Gislum.;Jens-Peter David.;John B Buse.; .
来源: N Engl J Med. 2025年392卷20期2001-2012页
The cardiovascular safety of oral semaglutide, a glucagon-like peptide 1 receptor agonist, has been established in persons with type 2 diabetes and high cardiovascular risk. An assessment of the cardiovascular efficacy of oral semaglutide in persons with type 2 diabetes and atherosclerotic cardiovascular disease, chronic kidney disease, or both is needed.
311. Dapagliflozin in Patients Undergoing Transcatheter Aortic-Valve Implantation.
作者: Sergio Raposeiras-Roubin.;Ignacio J Amat-Santos.;Xavier Rossello.;Rocío González Ferreiro.;Inmaculada González Bermúdez.;Diego Lopez Otero.;Luis Nombela-Franco.;Livia Gheorghe.;Jose L Diez.;Carlos Baladrón Zorita.;José A Baz.;Antonio J Muñoz García.;Victoria Vilalta.;Soledad Ojeda-Pineda.;José M de la Torre Hernández.;Juan G Cordoba Soriano.;Ander Regueiro.;Pascual Bordes Siscar.;Jorge Salgado Fernández.;Bruno Garcia Del Blanco.;Roberto Martín-Reyes.;Rafael Romaguera.;César Moris.;Sergio García Blas.;Juan A Franco-Peláez.;Ignacio Cruz-González.;Dabit Arzamendi.;Nieves Romero Rodríguez.;Felipe Díez-Del Hoyo.;Santiago Camacho Freire.;Francisco Bosa Ojeda.;Juan C Astorga Burgo.;Eduardo Molina Navarro.;Juan Caballero Borrego.;Valeriano Ruiz Quevedo.;Ángel Sánchez-Recalde.;Vicente Peral Disdier.;Eduardo Alegría-Barrero.;Javier Torres-Llergo.;Gisela Feltes.;José A Fernández Díaz.;Carlos Cuellas.;Gustavo Jiménez Britez.;Juan Sánchez-Rubio Lezcano.;Cristina Barreiro-Pardal.;Iván Núñez-Gil.;Emad Abu-Assi.;Andrés Iñiguez-Romo.;Valentín Fuster.;Borja Ibáñez.; .
来源: N Engl J Med. 2025年392卷14期1396-1405页
Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of heart-failure admission among high-risk patients. However, most patients with valvular heart disease, including those undergoing transcatheter aortic-valve implantation (TAVI), have been excluded from randomized trials.
314. Extended Reduced-Dose Apixaban for Cancer-Associated Venous Thromboembolism.
作者: Isabelle Mahé.;Marc Carrier.;Didier Mayeur.;Jean Chidiac.;Eric Vicaut.;Nicolas Falvo.;Olivier Sanchez.;Claire Grange.;Manuel Monreal.;Juan J López-Núñez.;Remedios Otero-Candelera.;Grégoire Le Gal.;Erik Yeo.;Marc Righini.;Helia Robert-Ebadi.;Menno V Huisman.;Frederikus A Klok.;Peter Westerweel.;Giancarlo Agnelli.;Cecilia Becattini.;Aristotelis Bamias.;Kostas Syrigos.;Sebastian Szmit.;Adam Torbicki.;Peter Verhamme.;Anthony Maraveyas.;Alexander T Cohen.;Cihan Ay.;Céline Chapelle.;Guy Meyer.;Francis Couturaud.;Patrick Mismetti.;Philippe Girard.;Laurent Bertoletti.;Silvy Laporte.; .
来源: N Engl J Med. 2025年392卷14期1363-1373页
In patients with active cancer and venous thromboembolism, whether extended treatment with a reduced dose of an oral anticoagulant is effective in preventing recurrent thromboembolic events and decreasing bleeding is unclear.
|